Relief Therapeutics and NeuroX have entered into a definitive agreement to merge, forming a new entity, MindMaze Therapeutics Holding SA, focused on advancing AI-driven neurotherapeutics for neurological diseases.

Information on the Target

Relief Therapeutics Holding SA is a biopharmaceutical firm dedicated to developing innovative treatment options for rare and unmet medical conditions. The company focuses on advancing treatment paradigms in specialty areas while leveraging its expertise in drug delivery systems and repurposing existing drugs. With a strong commitment to improving patients' lives, Relief has successfully brought several treatment options to market through strategic partnerships and collaborations.

NeuroX Group SA, a successor to MindMaze, specializes in digital neurotherapeutics and brain health technologies. Following a recent acquisition of key assets of the MindMaze brand, NeuroX has created a clinically validated portfolio of products aimed at addressing significant neurological diseases and brain disorders. By integrating cutting-edge technology into its offerings, NeuroX is positioned to revolutionize the delivery of neurotherapeutic interventions.

Industry Overview in Switzerland

The healthcare technology industry in Switzerland is rapidly evolving, driven by advancements in digital health and an increasing emphasis on precision medicine. Renowned for its high-quality research and development capabilities, Switzerland is home to numerous biotech